Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates 
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
CAMBRIDGE, Mass., Sept. 26, 2016 -- CoLucid Pharmaceuticals, Inc. (Nasdaq:CLCD), a biopharmaceutical company that is developing lasmiditan oral tablets for the acute treatment of migraine in adults, with or without aura, announced today it will provide a corporate overview at the Ladenburg Thalmann 2016 Healthcare Conference, being held in New York City on September 27, 2016.
| Ladenburg Thalmann 2016 Healthcare Conference | |
| Date: | Tuesday, September 27 |
| Time: | 11:30am Eastern Time |
| Location: | Sofitel Hotel New York, Odeon Room |
| Webcast: | http://wsw.com/webcast/ladenburg2/clcd |
About CoLucid Pharmaceuticals, Inc.
CoLucid was founded in 2005 and is developing lasmiditan oral tablets for the acute treatment of migraine headaches in adults and intravenous lasmiditan for the acute treatment of headache pain associated with migraine in adults in emergency room and other urgent care settings.
CONTACT Thomas Mathers Chief Executive Officer CoLucid Pharmaceuticals, Inc. (857) 285-6494 Hans Vitzthum Managing Director LifeSci Advisors, LLC. (212) 915-2568
